Samsung Bioepis Launches Ontruzant (trastuzumab, biosimilar) for Early and Metastatic HER2-Overexpressing Breast Cancer in Brazil

August 11, 2020 Auto Bot Biosimilar, Biosimilars, Brazil, breast cancer, Early, Launches, Metastatic, Samsung Bioepis, trastuzumab 0

Shots:

  • The company launches its first oncology treatment Ontruzant (trastuzumab), a biosimilar referencing Herceptin in Brazil. The biosimilar has received ANVISA’s approval for the treatment of metastatic HER2-overexpressing BC, early HER2-overexpressing BC, and advanced gastric cancer
  • Ontruzant is being supplied to SUS through a PDP b/w Samsung Bioepis & Bionovis and Bio-Manguinhos. This the second product to be launched in Brazil followed by Brenzys, both in partnership with local partners
  • Ontruzant is now available in six markets: Brazil, Australia, EU, the US, Ukraine and Korea. The therapy has received EC’s MAA in Nov’2017 and the US FDA’s approval in Jan’2019

Click here ­to­ read full press release/ article | Ref: Samsung Bioepis | Image: PharmaShots